Dendreon
1700 Saturn Way
Seal Beach
CA
90740
United States
Tel: 206-256-4545
Fax: 206-256-0571
Website: http://www.dendreon.com/
322 articles about Dendreon
-
Dendreon Appoints Jason O’Neill as Chief Executive Officer
6/8/2020
Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced the appointment of Jason O’Neill as chief executive officer, effective June 1, 2020. O’Neill brings extensive pharmaceutical leadership experience to Dendreon, with prominent roles in the are
-
Dendreon Signs Union City Lease Agreement
12/18/2019
Company Extends Long-Time Presence for Cutting-Edge Immunotherapy Manufacturing Facility through 2029
-
Dendreon Completes Enrollment of Phase 3 ProVent Clinical Trial Evaluating Sipuleucel-T in Men on Active Surveillance
10/30/2019
Target Enrollment of 450 Achieved Early Due to High Demand Topline Results Expected in 2023
-
Dendreon to Present Long-Term Survival and HEOR Data at American Urological Association Annual Meeting
5/3/2019
Dendreon Pharmaceuticals announced that data on long-term clinical outcomes and health economics and outcomes research related to sipuleucel-T will be presented at the American Urological Association Annual Meeting, taking place May 3-6, 2019 in Chicago.
-
Decipher Biosciences Announces Research Collaboration with Dendreon to Identify Genomic Drivers of Patient Response to Sipuleucel-T
2/15/2019
Decipher Biosciences, a leader in the field of urologic cancer genomics, today announced a research collaboration with Dendreon Pharmaceuticals
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
Movers and Shakers for Sept. 4
9/4/2018
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look. -
Bristol-Myers Squibb has appointed Christopher Boerner to replace Murdo Gordon, who left the company on August 3. Boerner will take on the positions of executive vice president and chief commercial officer, effective immediately.
-
Biotech Movers and Shakers for Aug. 13
8/13/2018
GSK's Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let's take a look at some of those! -
Dendreon Appoints Bruce A. Brown, M.D. to Lead R&D Organization
11/8/2017
In this role, Dr. Brown will lead all functions in the company’s R&D organization, including research and discovery, clinical development and exploration of Dendreon’s therapeutic platform for other oncology indications.
-
Sanpower Group Completes The Acquisition Of Dendreon From Valeant
6/29/2017
-
Dendreon Announces New Findings Demonstrating Durable And Robust Killer T-Cell Response With PROVENGE
6/5/2017
-
Dendreon Announces Results Of New PROCEED Registry Analysis Showing Overall Survival Benefit With PROVENGE In Men With Metastatic Prostate Cancer
5/15/2017
-
Ex-Dendreon CEO Returns to Biotech, Throws a Lifeline to Struggling Nivalis
4/19/2017
-
Debt-Ridden Valeant Offloads Dendreon for $819.9 Million Cash
1/11/2017
-
In Juno Patient Deaths, Echoes Seen Of Earlier Failed Company Dendreon
7/11/2016
-
Former Dendreon CEO Pulls in $48 Million for Latest Startup Alpine Immune Sciences
6/13/2016
-
Why Ex-Dendreon CEO's New Startup Could Succeed Where Dendreon Failed
3/5/2015
-
Valeant Starts Chopping Dendreon Employees
3/5/2015
-
A Peek Inside Ex-Dendreon CEO, Amgen Scientists' New Startup Alpine Immune Sciences
3/4/2015